Santhera Pharmaceuticals’ Post

$LTP - Last night the Australian Stockbrokers Foundation awarded Alpine Capital Best #IPO of The Year for the listing of LTR Pharma in November 2023. Since IPO, LTR Pharma stock has traded up 300% above its listing price of 20c following the announcement of the exceptional initial SPONTAN results, with full trial results anticipated in the coming months. Alpine Capital has been instrumental in this achievement, acting as the Lead Manager for LTR Pharma's successful IPO. Their expertise and strategic guidance have played a crucial role in navigating the complexities of the public listing process and positioning LTR Pharma for ongoing success. LTR Pharma's primary focus is on enhancing men's physical and mental health through the commercialisation of their groundbreaking nasal spray treatment for Erectile Dysfunction (ED). ED is a significant health issue affecting millions of men worldwide, often leading to diminished self-esteem and strained relationships. LTR Pharma's lead product, SPONTAN, offers a unique solution with its innovative mechanism of action. SPONTAN distinguishes itself from existing ED therapies through its intranasal delivery technology of a PDE5 inhibitor. The nasal cavity, being a highly vascular part of the body, facilitates rapid and even absorption of the drug, allowing it to take effect within 10 minutes or less. This swift action empowers men to regain control over the timing, spontaneity, and enjoyment of their sexual experiences, making SPONTAN a revolutionary advancement in ED treatment. Well done to everyone involved. Charles Reed James Emonson Thomas Schoenmaker Phil Cawood Malcolm Nutt Lee Rodne Peter McLennan Haley Chartres JMM

📉 VKTX takes a tumble, dropping 10.9% 📉 What caused the dip? Stay informed about market movers! #VKTX #StockMarket #Investing #Finance ## Viking Therapeutics Inc (VKTX) Sees 10.9% Drop in Shares Despite Lack of News Viking Therapeutics Inc (VKTX) shares are trading lower by 10.9% to $63.95 Monday afternoon, despite a lack of company-specific news for the session. The stock experienced marked strength in February after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints. However, VKTX has also seen volatility in recent sessions after the company announced its public offering of 6.471 million common shares at $85 per share. ### Is VKTX A Good Stock To Buy? Investors evaluating VKTX may consider various factors beyond just price movements. Viking Therapeutics does not pay a dividend, but it has other avenues to return value to shareholders, such as through buyback programs. Buyback programs are variable and can impact share prices by providing a support level for demand. Monitoring news for announcements on buyback programs can give insight into the company's strategic decisions. This article is not intended as investment advice. Investors should conduct thorough research and analysis before making any investment decisions in VKTX or any other stock. Read the full article at: https://lnkd.in/gCSHB7Hd

#AEMD - Why Arcutis Biotherapeutics Shares Are Trading Higher By 29 Here Are 20 Stocks Moving Premarket Benzinga Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) rose sharply in today's pre-market trading after the company reported better-than-expect...

$72C1 - Will Eiger BioPharmaceutica price increase in March 2024? 30 for 1 Split on 8th of January 2024: About 60.0% of the company shares are owned by institutions such as pension funds. The company has Price-to-Book (P/B) ratio of 0.63. In the past many companies with similar price-to-book ratios have beat the market. Eiger BioPharmaceuticals recorded a loss per share of 2.12. The entity had not issued any dividends in recent years. The firm had 30:1 split on the 4th of November 2023. https://lnkd.in/gwTZk7sv #stocks #stocktwits #thematic_portfolio

$AZYO - Is Aziyo BiologicsInc a good short-term buy? Symbol was renamed to ELUT on 7th of September 2023.: About 70.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.18. Aziyo BiologicsInc had not issued any dividends in recent years. #stocks #stocktwits #thematic_portfolio

Everybody in antitrust is talking about ECJ’s ruling in the Illumina/Grail saga, but there’s also another interesting angle to the story: the perspective of Illumina’s shareholders that are now staring at an almost 8 bln. USD gap between the price paid by Illumina and the divestment price of Grail (current market capitalization approx. 400 mln. USD as of today). In an ironic way, the Commision was doing a favour to Illumina by trying to block the merger. It is almost surreal, purely from a valuation perspective, how much economic damage has this deal done for Illumina’s shareholders, even if the company won the legal battle in the end. A true Pyrrhic victory in the most literal sense. https://lnkd.in/dMj393Tj

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is seeking to relist its stocks on the #Nasdaq with a re-domiciliation to the United States under a scheme of arrangement that would see Delaware-based Anteris Technologies Global Corp become the parent company of the Anteris Group. The new holding company would then seek a listing on the Nasdaq – alongside a secondary listing of its CDIs on the ASX – and undertake an initial public offering (IPO) targeted at, but not restricted to, US investors. AVR plans to complete the relisting and the IPO by the end of 2024, targeting between US$75 million and US$100 million. More at #Proactive #ProactiveInvestors #NasdaqListing #IPO #Biotech #Biopharmaceutcials #MedicalDevices http://ow.ly/PxuI105FeNJ

Standard BioTools, an analytical laboratory instrument manufacturing company, completed the merger with SomaLogic, a protein biomarker discovery and clinical diagnostics company, in a $1bn deal. “This is an exciting day as we officially bring together the innovative multi-omic technologies and incredible talent of Standard BioTools and SomaLogic to create one company that is a diversified leader in life sciences tools. We are moving forward with a significantly expanded and diversified platform, greater financial flexibility and an accelerated path to profitability. As a larger well-capitalized company, we have greater capacity to self-fund future growth initiatives and accelerate research insights across the industry, better serving our customers and delivering sustainable long-term growth for our shareholders. We are focused on ensuring a smooth transition and achieving our stated commitments,” Michael Egholm, Standard BioTools President and CEO. On December 29, 2023, independent proxy advisory firm Glass Lewis recommended all Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic. SomaLogic (led by Adam Taich) was advised by Perella Weinberg, Cowen Inc., Fenwick & West (led by David Michaels, Julia Forbess and Ethan Skerry), Gilmartin Group LLC (led by Marissa Bych) and Joele Frank (led by Daniel Katcher). Financial advisors were advised by Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates (led by Blair Thetford). Standard BioTools (led by Michael Egholm) was advised by Centerview Partners, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. , CapComm Partners (led by Peter DeNardo) and Collected Strategies (led by Dan Moore and Nick Lamplough). #MergersAcquisitionsDivestitures #Biotechnology #Manufacturing

Emcure Pharma gets Sebi approval for IPO: What we know Full Article Link >>> https://lnkd.in/gd94mS4D Welcome To Latest IND >> Fastest World News Jun 20, 2024 02:23 PM IST The IPO includes fresh equity sale worth ₹800 crore and an OFS of 1.36 crore equity shares by promoters and existing shareholders. Emcure Pharma has received Sebi’s nod for the IPO. The company is likely to launch the issue in the […] . . Latest IND . . . . #trendingnews #newstrending #trendingtopicnews #lifestyle #business #news #healthylifestyle #smallbusiness #supportsmallbusiness #lifestyleblogger #luxurylifestyle #businessowner #businesswoman #smallbusinessowner #businessnews